(2S,4R)-N-((S)-3-(4-((4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)ethynyl)-1,4'-bipiperidin-1'-ylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)-3-oxopropyl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide

ID: ALA4765108

PubChem CID: 162660831

Max Phase: Preclinical

Molecular Formula: C58H63F3N10O6S2

Molecular Weight: 1117.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1cc([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NN2CCC(N3CCC(C#Cc4ccc(N5C(=S)N(c6ccc(C#N)c(C(F)(F)F)c6)C(=O)C5(C)C)cc4)CC3)CC2)c2ccc(-c3scnc3C)cc2)C(C)C)on1

Standard InChI:  InChI=1S/C58H63F3N10O6S2/c1-34(2)51(49-27-35(3)66-77-49)54(75)69-32-45(72)29-48(69)53(74)64-47(39-11-13-40(14-12-39)52-36(4)63-33-79-52)30-50(73)65-68-25-21-42(22-26-68)67-23-19-38(20-24-67)8-7-37-9-16-43(17-10-37)71-56(78)70(55(76)57(71,5)6)44-18-15-41(31-62)46(28-44)58(59,60)61/h9-18,27-28,33-34,38,42,45,47-48,51,72H,19-26,29-30,32H2,1-6H3,(H,64,74)(H,65,73)/t45-,47+,48+,51-/m1/s1

Standard InChI Key:  FCVKNNCCYORVCP-CIFRGWANSA-N

Molfile:  

 
     RDKit          2D

 79 87  0  0  0  0  0  0  0  0999 V2000
   23.8237  -10.4257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1138  -10.0171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1128  -10.8367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9936   -6.3480    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   20.7902   -6.5667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5798   -5.7690    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   20.0871   -7.8007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0860   -8.6244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7981   -9.0375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5119   -8.6239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5091   -7.7971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7963   -7.3919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2249   -9.0331    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.3116   -9.8498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.5229   -9.3059    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.9709   -8.6955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1436   -7.8917    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   19.3752   -7.3923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5045   -6.1557    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   21.7011  -10.3976    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.6599   -6.9780    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.5761   -9.9954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.9807   -9.2835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5701   -8.5772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7510   -8.5816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3442   -9.2982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7612  -10.0016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7977   -9.2779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6190   -9.2739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4403   -9.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8517   -9.9834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6695   -9.9814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.0784   -9.2693    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.6676   -8.5577    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8436   -8.5581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.8951   -9.2676    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.3074   -9.9808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.1251   -9.9818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.5368   -9.2713    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.1286   -8.5581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.3047   -8.5554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3543   -9.2709    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.7667   -8.5589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5880   -8.5585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.9963   -7.8465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3537   -7.8472    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.8176   -7.8461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2274   -8.5606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.0480   -8.5606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.4570   -7.8480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.0437   -7.1340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2245   -7.1375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5874   -7.1348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.9956   -6.4228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5867   -5.7153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.9153   -4.9636    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.3036   -4.4130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6001   -4.8260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7664   -5.6294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.7183   -4.7875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2708   -5.3975    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.9688   -4.0096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.7718   -3.8335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.4204   -3.3996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.6708   -2.6177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.6173   -3.5716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.3852   -4.3783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.0960   -3.9637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9240   -3.1565    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.1069   -3.0775    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   38.8475   -4.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.2773   -7.8439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.7630   -8.5083    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   39.5439   -8.2544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.5424   -7.4330    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   38.7606   -7.1779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.5107   -6.3970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.8170   -6.4224    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.8533   -4.4944    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  5  4  1  0
  6  5  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12  7  1  0
 13 14  1  0
 14  2  1  0
  2 15  1  0
 15 16  1  0
 16 13  1  0
 10 13  1  0
 16 17  2  0
  7 18  1  0
 12  5  1  0
  5 19  1  0
 14 20  2  0
 18 21  3  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 22  1  0
 28 29  3  0
 23 28  1  0
 29 30  1  0
 30 31  1  0
 30 35  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 36 37  1  0
 36 41  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 40 41  1  0
 33 36  1  0
 39 42  1  0
 26 15  1  0
 42 43  1  0
 43 44  1  0
 45 44  1  6
 43 46  2  0
 45 47  1  0
 47 48  2  0
 48 49  1  0
 49 50  2  0
 50 51  1  0
 51 52  2  0
 52 47  1  0
 45 53  1  0
 53 54  1  0
 55 54  1  6
 55 56  1  0
 56 57  1  0
 57 58  1  0
 58 59  1  0
 59 55  1  0
 56 60  1  0
 60 61  2  0
 60 62  1  0
 62 63  1  6
 62 64  1  0
 64 65  1  0
 64 66  1  0
 63 67  2  0
 67 68  1  0
 68 69  2  0
 69 70  1  0
 70 63  1  0
 68 71  1  0
 72 73  1  0
 73 74  1  0
 74 75  2  0
 75 76  1  0
 76 72  2  0
 50 72  1  0
 76 77  1  0
 54 78  2  0
 58 79  1  1
M  END

Alternative Forms

1. Parent:

   

   ALA4765108

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1117.33

Molecular Weight (Monoisotopic): 1116.4326

AlogP: ┄

#Rotatable Bonds: ┄

Polar Surface Area: ┄

Molecular Species: ┄

HBA: ┄

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): ┄

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: ┄

CX LogD: ┄

Aromatic Rings: ┄

Heavy Atoms: ┄

QED Weighted: ┄

Np Likeness Score: ┄

References

1. Kargbo RB.  (2021)  Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.,  12  (3): [PMID:33738051] [10.1021/acsmedchemlett.1c00059]

2. Tilley, W D WD, Marcelli, M M, Wilson, J D JD and McPhaul, M J MJ.  1989-01  Characterization and expression of a cDNA encoding the human androgen receptor.  [PMID:2911578]

3. Hamann, L G LG and 8 more authors.  1998-02-12  Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.  [PMID:9484511]

4. Wang, L G LG, Liu, X M XM, Kreis, W W and Budman, D R DR.  1998-05-01  Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.  [PMID:10076535]

5. Giwercman, A A and 7 more authors.  2000-06  Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene.  [PMID:10852459]

6. Fuhrmann, U U and 7 more authors.  2000-12-28  Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.  [PMID:11150172]

7. Handratta, Venkatesh D VD and 10 more authors.  2005-04-21  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.  [PMID:15828836]

8. Kinoyama, Isao I and 16 more authors.  2006-01-26  (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.  [PMID:16420057]

9. Larsson, Anders A, Eriksson, Leif A LA, Andersson, Patrik L PL, Ivarson, Per P and Olsson, Per-Erik PE.  2006-12-14  Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.  [PMID:17149866]

10. van Oeveren, Arjan A and 11 more authors.  2007-03-15  Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.  [PMID:17267219]

11. Fensome, Andrew A and 19 more authors.  2008-03-27  Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).  [PMID:18318463]

12. Li, Jie Jack JJ and 23 more authors.  2008-11-13  Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications.  [PMID:18921992]

13. Tran, Chris C and 18 more authors.  2009-05-08  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  [PMID:19359544]

14. Schlienger, Nathalie N and 12 more authors.  2009-11-26  Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.  [PMID:19856921]

15. Jung, Michael E and 6 more authors.  2010-04-08  Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).  [PMID:20218717]

16. Zhou, Hai-Bing HB, Lee, Jae Hak JH, Mayne, Christopher G CG, Carlson, Kathryn E KE and Katzenellenbogen, John A JA.  2010-04-22  Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.  [PMID:20355713]

17. Arhancet, Graciela B and 14 more authors.  2010-08-26  Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.  [PMID:20672820]

18. Yoshino, Hitoshi H and 16 more authors.  2010-12-01  Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.  [PMID:21050768]

19. Guo, Chuangxing C and 28 more authors.  2011-11-10  Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.  [PMID:21936524]

20. Hasui, Tomoaki and 18 more authors.  2011-12-22  Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.  [PMID:22074142]

21. Yamamoto, Satoshi S and 13 more authors.  2012-01-01  Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.  [PMID:22094279]

22. Guo, Chuangxing C and 11 more authors.  2012-01-15  Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.  [PMID:22197140]

23. Yamamoto, Satoshi S and 10 more authors.  2012-04-01  Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.  [PMID:22391033]

24. Poutiainen, Pekka K PK and 6 more authors.  2012-07-26  Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.  [PMID:22746350]

25. Yamamoto, Satoshi S and 9 more authors.  2013-01-01  Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.  [PMID:23199477]

26. Liedtke, Andy J AJ and 7 more authors.  2013-03-28  Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.  [PMID:23432095]

27. Purushottamachar, Puranik P and 8 more authors.  2013-06-27  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.  [PMID:23713567]

28. Maruyama, Keisuke K and 6 more authors.  2013-07-15  Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist.  [PMID:23768907]

29. Akita, Kazumasa K and 5 more authors.  2013-11-15  A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate.  [PMID:24177288]

30. Richardson, Timothy I TI and 18 more authors.  2011-02-10  Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.  [PMID:24900294]

31. Li, Huifang H and 8 more authors.  2014-08-14  Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.  [PMID:25062331]

32. Ullrich, Thomas T and 21 more authors.  2014-09-11  3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.  [PMID:25121964]

33. Gege, Christian C, Schlüter, Thomas T and Hoffmann, Thomas T.  2014-11-15  Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.  [PMID:25305688]

34. Sundén, Henrik H and 6 more authors.  2015-02-12  Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.  [PMID:25646649]

35. Aikawa, Katsuji K and 11 more authors.  2015-05-15  Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I.  [PMID:25862209]

36. Jadhavar, Pradeep S PS and 20 more authors.  2016-11-01  Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.  [PMID:27717544]

37. Shibata, Norihito N and 11 more authors.  2018-01-25  Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.  [PMID:28594553]

38. Unwalla, Ray R and 18 more authors.  2017-07-27  Structure-Based Approach To Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators.  [PMID:28696695]

39. Nishiyama, Yuko Y and 6 more authors.  2018-07-12  Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.  [PMID:30034593]

40. Rew, Yosup Y and 19 more authors.  2018-09-13  Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).  [PMID:30091920]

41. Dalal, Kush K and 11 more authors.  2018-09-05  Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.  [PMID:30193215]

42. Hwang, Dong-Jin DJ and 7 more authors.  2019-01-24  New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.  [PMID:30525603]

43. Yu, Jiang J and 7 more authors.  2019-06-01  Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.  [PMID:30925341]

44. Du, Xiaohui X and 16 more authors.  2019-07-25  Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).  [PMID:31274313]

45. Tang, Qin and 12 more authors.  2020-04-15  Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.  [PMID:32114360]

46. He, Yali and 6 more authors.  2020-11-12  Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.  [PMID:33095584]

47. Wang, Ao; Wang, Yawan; Meng, Xin and Yang, Yushe.  2021-02-01  Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.  [PMID:33388655]

48. Zhang, Zhuming and 17 more authors.  2021-01-28  Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).  [PMID:33470111]

Source

Source(1):

• Scientific Literature